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Three tyrosine kinase inhibitors (TKIs), imatinib, nilotinib and dasatinib, are currently approved for the treatment of newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) patients. Although these drugs result in excellent responses in most patients, significant interpatient variability in overall response is observed. We have previously demonstrated that the degree of kinase inhibition achieved in vitro and in vivo is a critical variable of imatinib response 1, 2 in CP-CML patients, and that the degree of kinase inhibition mediated is closely related to the intracellular concentration of the drug achieved. 3 Importantly, the intracellular drug concentration is a result of the net effects of drug influx/efflux and plasma concentration, which can be influenced by many factors including concomitant therapies.
TKIs are generally well tolerated, however, side effects have been reported some of which, such as gastrointestinal problems, necessitate therapeutic intervention. Although the use of proton pump inhibitors (PPIs), including pantoprazole, esomeprazole and others, is contraindicated in patients taking dasatinib (at the direction of Bristol-Myers Squibb (BMS) due to the risk of reduced dasatinib exposure), they are widely prescribed in the greater community, and also frequently taken by patients on imatinib and nilotinib to control the documented gastric side effects. Data from the recent ENESTnd study indicated that up to 24% of patients treated with nilotinib concurrently received PPIs or H2 blockers. 4 Furthermore, up to 34% of patients treated on study CAMN107A2101 received these drugs, indicating that their coprescription is not uncommon. 4 PPIs have been reported to interact with the drug efflux transporters, ABCB1 and ABCG2. In this context, PPIs have been found to be both inhibitors and substrates. [5] [6] [7] We and others 3, 8, 9 have demonstrated that imatinib and nilotinib also interact with both ABCB1 and ABCG2 providing impetus for further investigation. As PPI's, and TKI, are also metabolized by cytochrome 450, drug interactions could potentially also occur during metabolism. Recently, Yin et al. 4 demonstrated only a modest decrease in nilotinib concentration when PPIs were coadministered with nilotinib in normal controls, suggesting that the increase in gastric pH afforded by the use of PPIs has no Accepted article preview online 16 October 2012; advance online publication, 20 November 2012 significant effect on the absorption of nilotinib, and that no significant negative effect could be demonstrated. Furthermore, reports of adverse cutaneous reactions, arising during concomitant imatinib and PPI therapy, 10 not present when either agent was used alone, suggest that drug interactions occur and may result in symptomatic presentations. However, interactions or efficacy at the level of the target leukemic cell, where ATP-dependent efflux transporters may have a role are yet to be elucidated.
In a more recent paper, Yin et al. 11 have demonstrated a modest superiority in the rate of major molecular response (MMR; reduction in BCR-ABL% (the % BCR-ABL relative to the control gene BCR, measured by quantitative reverse transcriptase PCR) to a level p0.1% International Scale (IS)) in patients treated with nilotinib and PPIs compared with that observed in patients receiving nilotinib alone (MMR rate at 12 months: nilotinib 300 mg b.i.d. with PPIs or H2 blockers 49.6% vs nilotinib alone 41%). To investigate interactions relevant to the leukemic cell, we have assessed the intracellular uptake and retention (IUR) 3, 12 of imatinib and nilotinib in the presence or absence of PPIs in cells collected after informed consent, from 10 newly diagnosed CP-CML patients. In addition, the effect of these drugs in combination on the degree of kinase inhibition mediated in vitro 1 has been investigated in five patients where sufficient cells were available. K562 cells and their ABCB1-overexpressing variant K562-DOX were also examined. The concentrations of pantoprazole chosen (5 and 10 mM) were based on documented clinically achievable concentrations 13, 14 with 200 mM chosen as the control concentration based on publications documenting the interactions of PPIs with efflux pumps in in vitro experiments. 5, 6 The imatinib IUR assay, which measures cell-associated drug concentrations, was performed as described previously. 3 In brief, 
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nilotinib in all five patients tested ( Table 1 ). The reduction was greater at 10 mM (mean 39% (range 20-59%) than at 5 mM (mean 18% (range 0-33%) and again supports the notion that pantoprazole results in an increase in the intracellular concentration of nilotinib, which translates to an increase in the degree of kinase inhibition mediated by the TKI (Table 1) .
To test the contribution of ABCB1 overexpression to the observed effect of pantoprazole, we compared, in K562 and K562-DOX cells, the IC50 imatinib and IC50 nilotinib in the presence of a low concentration (5 mM) of pantoprazole. In K562 cells, the IC50 nilotinib was reduced from 500 to 400 nM (20% reduction) in the presence of 5 mM pantoprazole. The IC50 imatinib in these cells remained unchanged. Although the IC50 imatinib also remained constant in K562 DOX cells in the presence and absence of pantoprazole, the IC50 nilotinib reduced by 58% from 600 to 250 nM. This indicates the increased intracellular concentration of nilotinib, in the presence of a low concentration of pantoprazole, translates to a significantly reduced IC50
nilotinib . This effect is greater in K562DOX (ABCB1 overexpressing) cells than in K562, suggesting involvement of ABCB1.
These data suggest that pantoprazole is blocking ABCB1-mediated nilotinib efflux, increasing its intracellular accumulation, and increasing the degree of kinase inhibition achieved, thus decreasing the IC50. Although we have concentrated this study on pantoprazole alone, due to the absence of sufficient patient cells, we have also demonstrated that the effect mediated by pantoprazole is statistically similar to that observed with esomeprazole in cell lines across a broad concentration range (data not shown).
In addition to the findings of Yin et al. 11 and Severino et al.
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studies with PPIs have demonstrated relevant in vitro interactions at clinically achievable concentrations, which have resulted in a 20% elevation in digoxin levels 6 as a result of ABCB1 inhibition. These interactions may also be exacerbated by cytochrome P450, CYP2C19 variant alleles, which impact significantly on the metabolism of PPIs. Based on CYP2C19 alleles patients are grouped into ultrarapid, rapid, intermediate and poor metabolizers. 15 A fivefold or greater difference in the plasma level of pantoprazole achieved between extensive and poor metabolizers has been observed suggesting plasma concentrations significantly higher than those used here may be reached in some patients. 16 It is therefore likely that the significant interaction observed with nilotinib may vary between patients depending on their CYP2C19 status, which will determine the level of active pantoprazole in the plasma. 17 Interestingly, here we demonstrate a differential effect of pantoprazole on the IUR and IC50 of these TKI. Although the intracellular concentration of nilotinib significantly increased with a concomitant decrease in IC50 nilotinib in the presence of pantoprazole, there was no significant effect on either the IC50 or IUR for imatinib. This observed decrease in IC50 nilotinib at the pantoprazole concentrations used here likely represents a scenario of significant relevance in the clinical setting. We have previously demonstrated that the degree of kinase inhibition achieved in vitro 1 with imatinib in newly diagnosed CP-CML patients provides a strong predictor of subsequent molecular response. This suggests that an increase in the degree of kinase inhibition mediated, as demonstrated here with pantoprazole, may result in an improvement in the clinical efficacy of nilotinib in CP-CML patients treated with this TKI, though the effect may be highly variable between patients and the long-term clinical outcomes are more difficult to predict. Importantly, these data are in keeping with the findings of Yin et al. 11 and provide support for the clinical observation of increased response rates in patients treated with both nilotinib and PPIs.
This study provides further evidence for the importance of the interaction of TKI with drug transporters, and demonstrates a significant interaction of pantoprazole with TKI, which in the case of nilotinib may be of clinical relevance. The findings of this study, and that of Yin et al. 11 , suggest further investigation of the effects of PPIs at both the cellular level and on molecular response, in larger TKI-treated patient populations may be warranted.
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Letters to the Editor
Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia Relapses after therapy-induced remissions remain a major challenge in cancer.
1,2 Molecular detection of minimal residual disease (MRD) is valuable in relapse prediction but its cellular basis remains largely unknown. [3] [4] [5] Delineating therapy-resistant cells (Figure 1a ) might inform new therapeutic strategies. 'Cancer stem cells', defined by xenografting, have been suggested to preferentially evade therapy, but evidence for persistence of phenotypically and functionally distinct cells in patients undergoing treatment is largely lacking.
We investigated the cells responsible for MRD in childhood acute lymphoblastic leukaemia (cALL) (for patient information see Table 1 ), where molecular MRD monitoring has had a practisechanging impact. 6 At presentation, cALLs comprise phenotypically distinct B-cell stages, including ProB-like (CD34 þ CD38 þ CD19 þ ), and cells dubbed 'Stem/B' coexpressing stem (CD34 þ CD38 À /low ) and B-cell (CD19 þ ) markers, seen only in leukaemia and preleukaemia. 7, 8 Although recent studies suggest that cells capable of propagating cALL in xenografts are plastic and extend beyond the Stem/B compartment, 9 its leukaemia-specificity provides a readily trackable biomarker in patients.
We first tracked the fate of leukaemic cells in MRD þ remission samples of three cALL patients who went on to relapse. In patient 1, BCR/ABL1 þ 'Stem/B' cells selectively persisted at remission, when no BCR/ABL1 þ leukaemic cells could be found in other B-cell compartments (Figures 1b and c) . A similar picture emerged from the analysis of ProB-like and Stem/B cells in remission samples in two TEL/AML1 cases (patients 2 and 3; Figure 1d and Supplementary Figure 1A) , suggesting that in patients with relapsed disease, cells within the Stem/B compartment are selectively chemoresistant, sustaining MRD and potentially initiating relapse.
In good-prognosis TEL/AML1 patients who achieved and remain in long-term complete (MRD À ) remission, we observed two behaviours: either Stem/B cells were eliminated with similar kinetics to ProB-like cells (one patient; Supplementary Figure 1B) or more slowly than their ProB counterparts (four patients; Figures 1e and f and Supplementary Figures 1C-E) .
Although variable, as might be expected in a setting where all leukaemic cells are ultimately eliminated, the preferential chemoresistance of Stem/B cells seen in most patients suggests enrichment of cells with specific functional properties within the Stem/B compartment. We speculated that the Stem/B phenotype may represent a surrogate biomarker for quiescence. At diagnosis, Stem/B cells were more quiescent (G 0 ) and less actively cycling (S-M-G 2 ) than leukaemic ProB cells, in all six patients analysed (Figure 1g) . Moreover, in all MRD samples investigated, we found that chemotherapy further selected for a rare but almost exclusively quiescent (G 0 ) population of Stem/B cells (Figure 1h) .
Our findings (i) suggest that quiescence contributes mechanistically to enhanced chemoresistance within the Stem/B compartment in cALL, a disease arguably derived from B-cell-restricted progenitors, which in contrast to stem cells normally cycle extensively; (ii) highlight the importance and feasibility of tracking rare but distinct cancer cell populations in patients undergoing therapy; and (iii) provide a conceptual framework for reframing the cancer stem cell debate in terms of patient relevance in the form of MRD-sustaining and relapse-initiating cells.
Our results merit comparison with those reported by Wilson et al. 10 These workers concluded that there was no specific cellular basis for therapy resistance in patients with cALL. This conclusion is in line with their view that there is no specific cellular basis for tumour propagation in xenograft models of cALL. 9 The conclusion of the Wilson et al. 10 study is limited by that fact it was solely based on immunophenotypic analysis of patient samples, lacking molecular-based polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH) analyses affording unambiguous discrimination between leukaemic and non-leukaemic cells. Nevertheless, in line with our own results, Wilson et al. 10 observed that the Stem/B population, still phenotypically detectable in 7/11 MRD þ remission samples, was proportionally spared during therapy relative to other compartments. Wilson et al. 10 chose to interpret these results as reflecting a chemotherapy-induced change Accepted article preview online 22 october 2012; advance online publication, 29 January 2013
